Galapagos is a midsized biotechnology company, with therapeutic programs based on proprietary disease modifying drug targets, and a focus on inflammation, orphan disease, and anti-infectives. Galapagos' approach is to develop drugs that stop or reverse a disease state using novel targets that are identified through a patent protected target discovery platform. Galapagos also provides access to its target and drug discovery platform through its services division, BioFocus and Argenta, which offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies.